Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 3/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8570131 | 0.98 | DPP4 (0.51) | MAPTALDH1A1HPGDMEN1GLA | |
| SCHEMBL8185448 | 0.88 | — | — | |
| SCHEMBL8827077 | 0.82 | MAPT (0.41) | MAPTALDH1A1HPGDMEN1GLA | |
| SCHEMBL8572801 | 0.81 | MEN1 (0.70) | MAPTALDH1A1HPGDMEN1GLA | |
| SCHEMBL278904 | 0.81 | DPP4 (0.65) | MAPTALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL10144207 | 0.81 | DPP4 (0.49) | MAPTALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL774352 | 0.81 | DPP4 (0.49) | MAPTALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL10020289 | 0.79 | DPP4 (0.51) | MAPTALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL607254 | 0.79 | DPP4 (0.69) | MAPTALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL8576605 | 0.79 | DPP4 (0.69) | MAPTALDH1A1HPGDMEN1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2868313-B2 | — | — | 1999-03-10 | — | — | JP | claimed |
| EP-0454511-B1 | N-substituted heterocycle derivatives, their preparation, compositions containing them | SANOFI SA (FR) | 1998-06-17 | — | — | EP | claimed |
| EP-0562936-A1 | Imidazolines N-substituted by a biphenylmethyl group, their preparation, the pharmaceutical compositions containing them | SANOFI (FR) | 1993-09-29 | — | — | EP | claimed |
| EP-0501892-A1 | Diazotized heterocyclic derivatives N-substituted by a biphenylmethyl group, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-09-02 | — | — | EP | claimed |
| EP-0454511-A1 | N-substituted heterocycle derivatives, their preparation, compositions containing them | SANOFI (FR) | 1991-10-30 | — | — | EP | claimed |
| WO-1991014679-A1 | HETEROCYCLIC N-SUBSTITUTED DERIVATIVES, THEIR PREPARATION AND THEPHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1991-10-03 | — | — | WO | claimed |
| EP-2595975-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | Corning Incorporated (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| WO-2012012278-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012278-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED (US) | 2012-01-26 | — | — | WO | disclosed |
| EP-1007035-A4 | POLYTHIOPHENE ANTI-TUMOR AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2000-11-22 | — | — | EP | disclosed |
| EP-0562936-A1 | Imidazolines N-substituted by a biphenylmethyl group, their preparation, the pharmaceutical compositions containing them | SANOFI (FR) | 1993-09-29 | — | — | EP | disclosed |
| EP-0519831-A1 | N-Substituted heterocyclic derivatives, their preparation, and pharmaceutical compositions containing them | SANOFI (FR) | 1992-12-23 | — | — | EP | disclosed |
| EP-0501892-A1 | Diazotized heterocyclic derivatives N-substituted by a biphenylmethyl group, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-09-02 | — | — | EP | disclosed |
| EP-0501892-A1 | Diazotized heterocyclic derivatives N-substituted by a biphenylmethyl group, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-09-02 | — | — | EP | disclosed |
| EP-0454511-A1 | N-substituted heterocycle derivatives, their preparation, compositions containing them | SANOFI (FR) | 1991-10-30 | — | — | EP | disclosed |
| WO-1991014679-A1 | HETEROCYCLIC N-SUBSTITUTED DERIVATIVES, THEIR PREPARATION AND THEPHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1991-10-03 | — | — | WO | disclosed |
| WO-1991014679-A1 | HETEROCYCLIC N-SUBSTITUTED DERIVATIVES, THEIR PREPARATION AND THEPHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1991-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | GPR35, GPR65, GPR68 | MAPT 3699/4885ALDH1A1 1572/4885HPGD 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.